2024
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront cost
2009
Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience
Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. Journal Of Clinical Oncology 2009, 27: 8558-8558. DOI: 10.1200/jco.2009.27.15_suppl.8558.Peer-Reviewed Original ResearchAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaAuto groupFirst remissionBetter progression-free survivalAggressive B-cell lymphomasMedian prior therapiesNon-relapse mortalitySingle institution experienceRole of transplantationNon-Hodgkin lymphomaLarge cell transformationB-cell lymphomaAllo transplantPrior therapyRelapse mortalityRelapsed diseaseALLO groupPoor OSAllogeneic transplantationLymphoblastic lymphomaMedian ageMedian timeWorse prognosis